Evaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactions

International Journal of Antimicrobial Agents

Volumn 27, Issue 6, 2006, Pages 557-560

  Johnson, David M ^a   Fritsche, Thomas R ^a   Sader, Helio S ^a   Jones, Ronald N ^a,b  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dalbavancin; Interaction studies; Lipoglycopeptide; Synergy

Indexed keywords

ANTIINFECTIVE AGENT; CLINDAMYCIN; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; OXACILLIN; PENICILLIN G; RIFAMPICIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; DILUTION; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG POTENTIATION; ENTEROCOCCUS FAECALIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PYOGENES; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-INFECTIVE AGENTS; DRUG INTERACTIONS; STAPHYLOCOCCUS AUREUS; TEICOPLANIN;

EID: 33646815618     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2005.12.015     Document Type: Article

References (15)

1. Gales A.C., Sader H.S., and Jones R.N. Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centers. Eur J Microbiol Infect Dis 11 (2005) 95-100
2. Raad I., Darouiche R., Vazquez J., et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens. Clin Infect Dis 40 (2005) 374-380
3. Anderegg T.R., Biedenbach D.J., and Jones R.N. Initial quality control evaluations for susceptibility testing of dalbavancin (BI397), an investigational glycopeptide with potent Gram-positive activity. J Clin Microbiol 41 (2003) 2795-2796
4. Klugman K.P., and Lonks J.R. Hidden epidemic of macrolide-resistant pneumococci. Emerg Infect Dis 11 (2005) 802-807
5. Lin G., Credito K., Ednie L.M., and Appelbaum P.C. Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob Agents Chemother 49 (2005) 770-772
6. Malabarba A., and Goldstein B.P. Origin, structure and activity in vitro and in vivo of dalbavancin. J Antimicrob Chemother 55 Suppl. 2 (2005) ii15-ii20
7. Bozdogan B., Esel D., Whitener C., Browne F.A., and Appelbaum P.C. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother 52 (2003) 864-868
8. Fridkin S.K., Hageman J.C., Morrison M., et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 352 (2005) 1436-1444
9. Streit J.M., Fritsche T.R., Sader H.S., and Jones R.N. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn Microbiol Infect Dis 48 (2004) 137-143
10. Willems R.J.L., Top J., van Santen M., et al. Global spread of vancomycin-resistant Enterococcus faecium from distinct nosocomial genetic complex. Emerg Infect Dis 11 (2005) 821-828
11. Dorr M.B., Jabes D., Cavaleri M., et al. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J Antimicrob Chemother 55 Suppl. 2 (2005) ii25-ii30
12. Jones R.N., Streit J.M., and Fritsche T.R. Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide. Int J Antimicrob Agents 23 (2004) 197-199
13. Seltzer E., Dorr M.E., Goldstein B.P., et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft tissue infections. Clin Infect Dis 37 (2003) 1298-1303
14. Isenberg HD. Synergism testing: broth microdilution checkerboard and broth macrodilution methods. In: Clinical microbiology procedures handbook, Vol. 2. Washington, DC: American Society for Microbiology; 2005. p. 5.12.1-23.
15. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Document M7-A6 (2003), NCCLS, Wayne, PA